---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-057883"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2026-05-15T20:44:23+00:00"
generated_at: "2026-05-15T21:02:24.715352+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology reports Q2 FY2026 net loss $26.6M; LYMPHIR revenue $1.7M, launch progressing

## Summary
- Net product revenues $1.7M in Q2 ($5.6M H1) vs $0 prior year; gross margin 80%.
- Net loss $26.6M vs $7.7M prior year, driven by $19.7M one-time CMO contract cancellation.
- Cash $2.6M at March 31; subsequent $11.5M warrant exercise and $10M debt tranche from Avenue Capital ($25M facility).
- 83% of target accounts on formulary or in review; near 100% payer coverage; initial European shipment.
- Hired Jefferies as exclusive financial advisor to evaluate strategic alternatives; combined cash runway through Nov 2026.

## SEC filing metadata
- accession: 0001213900-26-057883
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2026-05-15T20:44:23+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/0001213900-26-057883-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea0291035-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-057883
- JSON: https://secwatch.observer/filing/0001213900-26-057883.json
- Plain text: https://secwatch.observer/filing/0001213900-26-057883.txt

## Key facts
- Earnings Releases
  CITIUS ONCOLOGY, INC. reported the fiscal second quarter ended March 31, 2026 results: revenue $1.7 million.
  - Period: the fiscal second quarter ended March 31, 2026
  - Revenue: $1.7 million
  - Result: reported results
  source text: revenue milestones; and, ○ approximately $11.5 million in gross proceeds received May 5, 2026 from the exercise of certain outstanding warrants; and, ● Net product revenues of $1.7 million for the three months ended March 31, 2026, compared to no revenue for the three months ended March 31, 2025; and $5.6 million for the six months ended March 31, 2026, compared
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/0001213900-26-057883-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.